Follow on Google News News By Tag Industry News Country(s) Industry News
Follow on Google News | Quotient Clinical extends its Translational Pharmaceutics™ platform into cancer drug developmentBy: Quotient Clinical Clinical trials in cancer patients are becoming increasingly stratified and focused on specific patient sub-groups, which can increase the challenges of patient recruitment and the associated timelines. In turn, this can result in unpredictable drug product requirements and an inefficient supply chain. Quotient’s real-time manufacturing approach offers a number of advantages in this setting, including: 1) flexibility of drug product manufacturing in response to patient recruitment rates, with product typically being supplied in less than three weeks from notification; 2) customization of drug product dose and/or composition according to patient/study need, and in response to clinical data emerging from the on-going program; 3) increased efficiency of drug substance consumption. Mark Egerton, Chief Executive Officer of Quotient Clinical, said “Approximately 30% of the industry’s drug development pipeline is focused on cancer. We have developed our real-time manufacturing and supply capabilities to support this specialist area with first-in-patient and proof-of-concept programs. We have already supported multiple development programs in the UK and mainland Europe, and will shortly be embarking on a similar project in North America. In these, and other future programs, we will be helping our clients to accelerate their early development pipelines and increase overall R&D productivity.” End
Account Email Address Disclaimer Report Abuse
|
|